entertainment -WSS

entertainment

author：hotspot 2025-09-27 19:21:33 - browse：6441

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Biden calls for immediate release of Niger's president amid apparent coup

Wikipedia

focus

WSS

Stem cell clinics for heart failure: buyer be wary

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Neuroscience’s long legacy of racism

2 US Navy sailors arrested for allegedly spying for China

Nurses recount patients attacks

OTC birth control: A brief history of over the counter pill design

leisure time

entertainment

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

ChatGPT in medicine: STAT answers readers' burning questions

Intermittent fasting comes with a heart risk? Not so fast

Peter Hotez and the public health issue of online harassment

What the cancer research community can learn from the Covid response

Bright Health sells Medicare Advantage business to Molina

'Ancient DNA,' 23andMe reveal African American ancestries

Psychedelics group wrestles with new pharma identity

CVS Caremark has created a new ploy: the drug ‘rebate credit’

entertainment

Positive childhood experiences can help future health

Gene editing the human germline: What are the risks?

Readout Newsletter: Bluebird, CVS, Contineum

Stop the failed accountable care organization experiment

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

U.K. researchers warn about biases in medical devices, algorithms

explore

Wikipedia

focus

leisure time